-+ 0.00%
-+ 0.00%
-+ 0.00%

Lixte Biotechnology replaces stock options with RSUs for executives, directors

PUBT·04/17/2026 20:06:42
Listen to the news
Lixte Biotechnology replaces stock options with RSUs for executives, directors
  • Lixte Biotechnology Holdings swapped previously granted stock options for fully vested restricted share units on April 15, 2026.
  • Chief Executive Officer Geordan Pursglove had 350,000 options cancelled, replaced with 350,000 RSUs.
  • Chief Financial Officer Peter Stazzone had 50,000 options cancelled, replaced with 50,000 RSUs.
  • Directors received replacement awards totaling 100,000 RSUs, matching 100,000 options cancelled.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-017833), on April 17, 2026, and is solely responsible for the information contained therein.